Mean platelet volume predicts survival in patients with hepatocellular carcinoma and type 2 diabetes

Ji bin Yin, Ye Niu, Li yan Qian, Xin Zhang, Zhi-Ping Liu, Rui tao Wang

Research output: Contribution to journalArticle

Abstract

Background: Patients with hepatocellular carcinoma (HCC) having pre-existing type 2 diabetes (T2DM) have a poorer prognosis than those without T2DM. Moreover, accumulating evidence reveals that activated platelets play a crucial role in tumor and T2DM. The mean platelet volume (MPV) indicates platelet activation and is altered in malignancies. The present study aimed to investigate the clinical significance of MPV in patients with HCC having T2DM. Methods: This retrospective study performed between January 2010 and December 2013 included 331 patients with HCC (165 with T2DM and 166 without T2DM). The overall survival was compared, and the predictors of overall survival were analyzed. Results: The patients with T2DM had lower MPV levels than those without T2DM. Furthermore, the MPV levels significantly differentiated T2DM from non-T2DM. In addition, for patients with T2DM, the overall survival was significantly shorter in patients with low MPV levels than in those with high MPV levels. Multivariate analysis identified decreased MPV as an independent prognostic factor for overall survival only in patients with T2DM, but not in those without T2DM. Conclusion: Reduced MPV was a prognostic factor for poor outcome in patients with HCC and T2DM.

Original languageEnglish (US)
Pages (from-to)120-127
Number of pages8
JournalDiabetes Research and Clinical Practice
Volume151
DOIs
StatePublished - May 1 2019

Fingerprint

Mean Platelet Volume
Type 2 Diabetes Mellitus
Hepatocellular Carcinoma
Survival
Platelet Activation
Neoplasms
Blood Platelets
Multivariate Analysis
Retrospective Studies

Keywords

  • Hepatocellular carcinoma
  • Mean platelet volume
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Mean platelet volume predicts survival in patients with hepatocellular carcinoma and type 2 diabetes. / Yin, Ji bin; Niu, Ye; Qian, Li yan; Zhang, Xin; Liu, Zhi-Ping; Wang, Rui tao.

In: Diabetes Research and Clinical Practice, Vol. 151, 01.05.2019, p. 120-127.

Research output: Contribution to journalArticle

Yin, Ji bin ; Niu, Ye ; Qian, Li yan ; Zhang, Xin ; Liu, Zhi-Ping ; Wang, Rui tao. / Mean platelet volume predicts survival in patients with hepatocellular carcinoma and type 2 diabetes. In: Diabetes Research and Clinical Practice. 2019 ; Vol. 151. pp. 120-127.
@article{9618d0603e8e4dce9ef162947841b7a4,
title = "Mean platelet volume predicts survival in patients with hepatocellular carcinoma and type 2 diabetes",
abstract = "Background: Patients with hepatocellular carcinoma (HCC) having pre-existing type 2 diabetes (T2DM) have a poorer prognosis than those without T2DM. Moreover, accumulating evidence reveals that activated platelets play a crucial role in tumor and T2DM. The mean platelet volume (MPV) indicates platelet activation and is altered in malignancies. The present study aimed to investigate the clinical significance of MPV in patients with HCC having T2DM. Methods: This retrospective study performed between January 2010 and December 2013 included 331 patients with HCC (165 with T2DM and 166 without T2DM). The overall survival was compared, and the predictors of overall survival were analyzed. Results: The patients with T2DM had lower MPV levels than those without T2DM. Furthermore, the MPV levels significantly differentiated T2DM from non-T2DM. In addition, for patients with T2DM, the overall survival was significantly shorter in patients with low MPV levels than in those with high MPV levels. Multivariate analysis identified decreased MPV as an independent prognostic factor for overall survival only in patients with T2DM, but not in those without T2DM. Conclusion: Reduced MPV was a prognostic factor for poor outcome in patients with HCC and T2DM.",
keywords = "Hepatocellular carcinoma, Mean platelet volume, Type 2 diabetes mellitus",
author = "Yin, {Ji bin} and Ye Niu and Qian, {Li yan} and Xin Zhang and Zhi-Ping Liu and Wang, {Rui tao}",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.diabres.2019.04.012",
language = "English (US)",
volume = "151",
pages = "120--127",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Mean platelet volume predicts survival in patients with hepatocellular carcinoma and type 2 diabetes

AU - Yin, Ji bin

AU - Niu, Ye

AU - Qian, Li yan

AU - Zhang, Xin

AU - Liu, Zhi-Ping

AU - Wang, Rui tao

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Background: Patients with hepatocellular carcinoma (HCC) having pre-existing type 2 diabetes (T2DM) have a poorer prognosis than those without T2DM. Moreover, accumulating evidence reveals that activated platelets play a crucial role in tumor and T2DM. The mean platelet volume (MPV) indicates platelet activation and is altered in malignancies. The present study aimed to investigate the clinical significance of MPV in patients with HCC having T2DM. Methods: This retrospective study performed between January 2010 and December 2013 included 331 patients with HCC (165 with T2DM and 166 without T2DM). The overall survival was compared, and the predictors of overall survival were analyzed. Results: The patients with T2DM had lower MPV levels than those without T2DM. Furthermore, the MPV levels significantly differentiated T2DM from non-T2DM. In addition, for patients with T2DM, the overall survival was significantly shorter in patients with low MPV levels than in those with high MPV levels. Multivariate analysis identified decreased MPV as an independent prognostic factor for overall survival only in patients with T2DM, but not in those without T2DM. Conclusion: Reduced MPV was a prognostic factor for poor outcome in patients with HCC and T2DM.

AB - Background: Patients with hepatocellular carcinoma (HCC) having pre-existing type 2 diabetes (T2DM) have a poorer prognosis than those without T2DM. Moreover, accumulating evidence reveals that activated platelets play a crucial role in tumor and T2DM. The mean platelet volume (MPV) indicates platelet activation and is altered in malignancies. The present study aimed to investigate the clinical significance of MPV in patients with HCC having T2DM. Methods: This retrospective study performed between January 2010 and December 2013 included 331 patients with HCC (165 with T2DM and 166 without T2DM). The overall survival was compared, and the predictors of overall survival were analyzed. Results: The patients with T2DM had lower MPV levels than those without T2DM. Furthermore, the MPV levels significantly differentiated T2DM from non-T2DM. In addition, for patients with T2DM, the overall survival was significantly shorter in patients with low MPV levels than in those with high MPV levels. Multivariate analysis identified decreased MPV as an independent prognostic factor for overall survival only in patients with T2DM, but not in those without T2DM. Conclusion: Reduced MPV was a prognostic factor for poor outcome in patients with HCC and T2DM.

KW - Hepatocellular carcinoma

KW - Mean platelet volume

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=85064000967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064000967&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2019.04.012

DO - 10.1016/j.diabres.2019.04.012

M3 - Article

C2 - 30959147

AN - SCOPUS:85064000967

VL - 151

SP - 120

EP - 127

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

ER -